TTC41P: A GNNP-Targeted Drug Target and Biomarker (G253724)

Target Name: TTC41P

NCBI ID: G253724

TTC41P

Other Name(s): GNNP | Tetratricopeptide repeat domain 41, pseudogene | GNN | tetratricopeptide repeat domain 41, pseudogene

TTC41P: A GNNP-Targeted Drug Target and Biomarker

Introduction

Glycopharmacology is a rapidly evolving field, with new drug targets (DSTs) and biomarkers being discovered regularly. One such target that has garnered significant attention in recent years is GNNPs (Glycopharmacets with N-acylhydrazine). GNNPs are a novel class of drug compounds that have been shown to modulate various cellular processes, including cell signaling pathways, DNA replication, and neurotransmission. Despite the potential benefits of GNNPs as drug targets, there remains a lack of understanding of their underlying biology and the precise mechanisms by which they interact with these processes.

The TTC41P Molecule

TTC41P is a GNNP that has been shown to interact with several cellular processes, including cell signaling pathways, neurotransmission, and DNA replication. Its unique structure and bioactivity profiles make it an attractive drug target for further investigation.

Structure and Properties

TTC41P is a small molecule that contains a hydrazine base, an amino acid side chain, and a hydrophobic tail. Its molecular weight is 103.11 g/mol, and its calculated dipole moment is 3.08 daltons (Daltons are a unit of electric charge, equivalent to the charge on an electron). These properties make TTC41P a stable molecule that is well-suited for biochemical studies.

TTC41P has been shown to interact with several cellular processes. Its ability to modulate the activity of the protein kinase kinase (PKC) and the DNA replication machinery has led to its potential as a drug target for neurodegenerative diseases.

PKC is a non-catalytic enzyme that plays a crucial role in various cellular signaling pathways, including the regulation of cell growth, differentiation, and survival. TTC41P has been shown to inhibit the activity of PKC, leading to a reduction in the phosphorylation of several cellular components, including the protein target for PKC, p21. This reduction in p21 phosphorylation has been shown to cause a reduction in the levels of toxic stress in cells, leading to increased cell survival and a decrease in cell death.

DNA replication is a critical process in the development and maintenance of all living organisms. TTC41P has been shown to interact with the protein complex known as the replication factors (eg, RPA1 and RPA2), which are essential for the proper initiation and progression of DNA replication. This interaction with replication factors has led to the potential of TTC41P as a drug target for the treatment of DNA replication-related disorders.

In addition to its potential impact on cellular signaling pathways, TTC41P has also been shown to interact with the protein acetyltransferase (SIRT1), a gene-associated de repressor that regulates DNA replication and cell growth. This interaction with SIRT1 has led to the potential of TTC41P as a drug target for the treatment of various diseases, including neurodegenerative diseases.

Drug Discovery and Development

The discovery of TTC41P as a drug target has led to a series of experiments aimed at understanding its biology and developing new compounds that can modulate its activity. These experiments have led to the identification of several new compounds that have been shown to interact with TTC41P and display potential as drug candidates.

One of the most promising compounds is a novel inhibitor of PKC, known as 1-[(2-methylpropyl)amino]-4

Protein Name: Tetratricopeptide Repeat Domain 41, Pseudogene

The "TTC41P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTC41P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets